Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies.
KEAP1
Nrf2
ROS
alpha-lipoic acid
autophagy
cell migration
p62
prostate cancer cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Dec 2023
04 Dec 2023
Historique:
received:
21
09
2023
revised:
24
11
2023
accepted:
27
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
Alpha-lipoic acid (ALA) is a natural antioxidant dithiol compound, exerting antiproliferative and antimetastatic effects in various cancer cell lines. In our study, we demonstrated that ALA reduces the cell growth of prostate cancer cells LNCaP and DU-145. Western blot results revealed that in both cancer cells, ALA, by upregulating pmTOR expression, reduced the protein content of two autophagy initiation markers, Beclin-1 and MAPLC3. Concomitantly, MTT assays showed that chloroquine (CQ) exposure, a well-known autophagy inhibitor, reduced cells' viability. This was more evident for treatment using the combination ALA + CQ, suggesting that ALA can reduce cells' viability by inhibiting autophagy. In addition, in DU-145 cells we observed that ALA affected the oxidative/redox balance system by deregulating the KEAP1/Nrf2/p62 signaling pathway. ALA decreased ROS production, SOD1 and GSTP1 protein expression, and significantly reduced the cytosolic and nuclear content of the transcription factor Nrf2, concomitantly downregulating p62, suggesting that ALA disrupted p62-Nrf2 feedback loop. Conversely, in LNCaP cells, ALA exposure upregulated both SOD1 and p62 protein expression, but did not affect the KEAP1/Nrf2/p62 signaling pathway. In addition, wound-healing, Western blot, and immunofluorescence assays evidenced that ALA significantly reduced the motility of LNCaP and DU-145 cells and downregulated the protein expression of TGFβ1 and vimentin and the deposition of fibronectin. Finally, a soft agar assay revealed that ALA decreased the colony formation of both the prostate cancer cells by affecting the anchorage independent growth. Collectively, our in vitro evidence demonstrated that in prostate cancer cells, ALA reduces cell growth and counteracts both migration and invasion. Further studies are needed in order to achieve a better understanding of the underlined molecular mechanisms.
Identifiants
pubmed: 38069431
pii: ijms242317111
doi: 10.3390/ijms242317111
pmc: PMC10707055
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MIUR
ID : 2017FJSM9S_006
Références
CA Cancer J Clin. 2018 Sep;68(5):329-339
pubmed: 30191964
FEBS Lett. 2008 May 28;582(12):1667-71
pubmed: 18435927
AAPS PharmSciTech. 2018 Nov;19(8):3454-3461
pubmed: 30350252
Curr Med Chem. 2004 May;11(9):1135-46
pubmed: 15134511
Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745
pubmed: 28899199
Med Oncol. 2023 Jul 15;40(8):244
pubmed: 37453954
Evid Based Complement Alternat Med. 2023 Jul 18;2023:8618575
pubmed: 37496822
J Exp Clin Cancer Res. 2022 Mar 22;41(1):105
pubmed: 35317831
Autophagy. 2020 May;16(5):917-931
pubmed: 31362587
Dose Response. 2021 Dec 9;19(4):15593258211055023
pubmed: 34987331
Cancer Res Treat. 2021 Jul;53(3):685-694
pubmed: 33321563
Cancers (Basel). 2023 Jun 02;15(11):
pubmed: 37296999
Bratisl Lek Listy. 2014;115(10):611-6
pubmed: 25573726
J Pharmacol Exp Ther. 2006 Dec;319(3):1062-9
pubmed: 16990509
Nutr Res. 2010 Jun;30(6):403-9
pubmed: 20650348
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Ovarian Res. 2015 Jun 12;8:36
pubmed: 26063499
PLoS One. 2020 Jul 28;15(7):e0232565
pubmed: 32722676
FEBS Open Bio. 2020 Apr;10(4):607-618
pubmed: 32090494
Anticancer Res. 2017 Jun;37(6):2893-2898
pubmed: 28551626
Adv Cancer Res. 2014;122:281-320
pubmed: 24974185
Nutrients. 2022 May 31;14(11):
pubmed: 35684123
Cancer Drug Resist. 2021 Mar 19;4(1):96-124
pubmed: 35582006
Oxid Med Cell Longev. 2021 Jun 4;2021:6633419
pubmed: 34211631
Life Sci. 2018 Aug 15;207:15-22
pubmed: 29802942
Rev Bras Farmacogn. 2023;33(2):272-287
pubmed: 36778891
Apoptosis. 2005 Mar;10(2):359-68
pubmed: 15843897
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
Oncogene. 2011 Nov 24;30(47):4687-96
pubmed: 21666712
J Biol Chem. 2012 Oct 26;287(44):37570-82
pubmed: 22955280
Anticancer Drugs. 2013 Jul;24(6):555-65
pubmed: 23599020
Cells. 2018 Aug 29;7(9):
pubmed: 30158439
Oncogene. 2020 Apr;39(17):3604-3610
pubmed: 32060422
Eur J Pharmacol. 2010 Sep 1;641(1):29-34
pubmed: 20580704
Nutrients. 2015 Jan 06;7(1):321-34
pubmed: 25569626
Curr Opin Toxicol. 2018 Feb;7:28-36
pubmed: 29457143
Neurochem Int. 2016 May;95:63-74
pubmed: 26529297
Am J Pathol. 2001 Nov;159(5):1815-26
pubmed: 11696442
Int J Mol Sci. 2023 Oct 04;24(19):
pubmed: 37834333
Free Radic Biol Med. 2015 Nov;88(Pt B):199-204
pubmed: 26117325
Cancer Res. 2018 Nov 1;78(21):6040-6047
pubmed: 30327380
Cancer Lett. 2016 Feb 1;371(1):12-9
pubmed: 26604131
Mol Cancer Ther. 2011 Sep;10(9):1533-41
pubmed: 21878654
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409187
Exp Dermatol. 2022 Feb;31(2):143-153
pubmed: 34331820
Front Oncol. 2022 Jul 12;12:925379
pubmed: 35903701
Nat Rev Urol. 2014 Sep;11(9):508-16
pubmed: 25134829
Nutrients. 2023 Apr 01;15(7):
pubmed: 37049574
Urol Oncol. 2014 Jan;32(1):39.e11-8
pubmed: 23787295
Antioxidants (Basel). 2020 Apr 25;9(5):
pubmed: 32344912
Cell Death Dis. 2022 Dec 20;13(12):1060
pubmed: 36539411
Biochim Biophys Acta Gen Subj. 2023 Oct;1867(10):130430
pubmed: 37506854
Biochim Biophys Acta Mol Basis Dis. 2022 Oct 1;1868(10):166455
pubmed: 35680107
Mol Cell Endocrinol. 2016 Jan 5;419:113-23
pubmed: 26463583